Health
Sinopharm shares phase 2 data on inactivated COVID-19 vaccine – FierceBiotech
Sinopharm has published clinical data on its adjuvanted SARS-CoV-2–inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus.
Sinopharm has published clinical data on its adjuvanted SARS-CoV-2inactivated virus vaccine. The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the pandemic coronavirus.
Most of the frontrunners in the COVID-19 vaccine race are using relatively unproven approaches to immunization. BioNTech, in partnership with Pfizer, and Moderna are advancing mRNA vaccines, a type of prophylactic that has never been approved. AstraZen…
-
Noosa News14 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General18 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General7 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Business23 hours agoTop brokers name 3 ASX shares to buy next week 5 October 2025